Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DCTH vs CRMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CRMD Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)
CRMD Overall Winner
6-Pillar Tally: DCTH 3 – 3 CRMD
Matrix Metrics: DCTH 3 – 7 CRMD
As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Delcath Systems Inc (DCTH) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas CRMD carries 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin).
- Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. DCTH 35.9/100 SELL) and 1.20β · 107% Vol risk profile, whereas DCTH leads top-line expansion (+70.7% YoY revenue growth, 1.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About DCTH vs CRMD
DCTH
Delcath Systems Inc
$19.68
-4.23% 1D
Market Cap
$743.8M
TTM Revenue
$110M
Forward P/E
N/M
Beta / 30D Vol
1.63β · 131% Vol
Unified Composite Score
35.9
SELL
Tech 50.0
Fund 38.0
Flow 60.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
CRMD
Head-to-Head Winner
CorMedix Inc.
$4.92
+5.47% 1D
Market Cap
$384.7M
TTM Revenue
$1.05B
Forward P/E
49.0x
Beta / 30D Vol
1.20β · 107% Vol
Unified Composite Score
53.2
HOLD
Tech 60.0
Fund 60.0
Flow 69.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (DCTH 3 – 3 CRMD)
1. Valuation Multiples
CRMD
Forward P/E
N/M
49.0x
Trailing P/E
133.6x
2.4x
PEG Ratio
1.60x
3.79x
EV / Revenue
6.3x
N/M
2. Growth & Scale
DCTH
Revenue Growth (YoY)
+70.7%
-47.7%
Earnings Growth (YoY)
+750.0%
+6.7%
TTM Revenue (USD)
$110M
$1.05B
Market Cap
$743.8M
$384.7M
3. Profitability & Quality
CRMD
Gross Margin
87.6%
87.4%
Operating Margin
5.2%
41.0%
Net Profit Margin
6.0%
15.5%
Return on Equity (ROE)
5.4%
15.3%
4. Balance Sheet & Cash Flow
CRMD
Cash Generation (TTM)
$20M
$785M
Cash Flow Margin
18.3%
74.6%
Net Cash / Leverage
$53M Net Cash
$535M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
DCTH
Options Structure Phase
BREAKOUT
BREAKDOWN
Current IV / %ile
109.3% (43rd %ile)
56.3% (25th %ile)
Put/Call OI Skew
0.11x (Call-Skewed)
0.69x (Call-Skewed)
OBV Trend / Tech Phase
ACCUMULATION · Neutral
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
DCTH
OpEx & R&D Intensity
82.4% of Rev ($91M)
46.4% of Rev ($488M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
High-Margin Pricing Power Moat
Supply-Chain Role
Medical Devices Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: DCTH (3) vs CRMD (7)| Institutional Metric | DCTH | CRMD | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $743.8M | $384.7M | DCTH | |
| Trailing P/E Ratio | 133.6x | 2.4x | CRMD | |
| Forward P/E Ratio | N/M | 49.0x | CRMD | |
| Revenue Growth (YoY) | +70.7% | -47.7% | DCTH | |
| Operating Margin (TTM) | 5.2% | 41.0% | CRMD | |
| Net Profit Margin | 6.0% | 15.5% | CRMD | |
| Return on Equity (ROE) | 5.4% | 15.3% | CRMD | |
| 52-Week Range Position | 80% ($8–$23) | 3% ($5–$13) | DCTH | |
| Beta / 30D Volatility | 1.63β · 131% Vol | 1.20β · 107% Vol | CRMD | |
| Unified Institutional Score | 35.9 / 100 (SELL) | 53.2 / 100 (HOLD) | CRMD | |
| Trailing 12M Revenue (USD) | $110M | $1.05B | Scale | |
| Gross Profit Margin (TTM) | 87.6% | 87.4% | Quality | |
| PEG Ratio & EV / Revenue | 1.60x PEG · 6.3x EV/Rev | 3.79x PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $20M ($53M Net Cash) | $785M ($535M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DCTH +72.07 pp
3M Horizon
DCTH +56.57 pp
6M Horizon
DCTH +115.32 pp
1Y Horizon
DCTH +184.73 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DCTH Revenue | CRMD Revenue | DCTH Op. Margin | CRMD Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -6250.4% | CRMD |
| FY2019 | N/A | $0M | N/A | -7416.3% | CRMD |
| FY2020 | N/A | $0M | N/A | -11378.4% | CRMD |
| FY2021 | $0M | $0M | -690.0% | -15417.5% | DCTH |
| FY2022 | $0M | $0M | -1245.1% | -46819.9% | DCTH |
| FY2023 | $0M | N/A | -1849.0% | N/A | DCTH |
| FY2024 | $40M | $40M | -33.4% | -51.4% | DCTH |
| FY2025 | $90M | $310M | 0.8% | 48.2% | CRMD |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
DCTH
BREAKOUT
Current IV
109.3%
IV Percentile
43rd %ile
Put/Call OI Skew
0.11x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CRMD
BREAKDOWN
Current IV
56.3%
IV Percentile
25th %ile
Put/Call OI Skew
0.69x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
DCTH Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
82.4% of Rev ($91M)
90D Engineering Disclosures
0 Published
CRMD Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
46.4% of Rev ($488M)
90D Engineering Disclosures
0 Published
Investor FAQ DCTH vs CRMD Key Questions & Quantitative Answers
As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Delcath Systems Inc (DCTH) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas CRMD carries 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin). Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. DCTH 35.9/100 SELL) and 1.20β · 107% Vol risk profile, whereas DCTH leads top-line expansion (+70.7% YoY revenue growth, 1.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with CRMD at -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DCTH cumulative revenue shifted +125.0% while CRMD shifted +675.0%. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus 46.4% of Rev ($488M) (0 disclosures) for CRMD.
CRMD screens cheaper on headline valuation multiples. DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin), whereas CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus CRMD (15.3% ROE) capital efficiency.
In options market volatility and institutional positioning, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk). By comparison, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CRMD vs DCTH · Reverse Pair
CRMD vs VTVT
· Sector Peer
CRMD vs CAPR
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal